| Literature DB >> 24216389 |
Sarah Vinjé1, Erik Stroes, Max Nieuwdorp, Stan L Hazen.
Abstract
Recent studies reveal a potential contribution of intestinal microbes in the expression of certain human cardio-metabolic diseases. The mechanisms through which intestinal microbiota and/or their metabolic products alter systemic homoeostasis and cardio-metabolic disease risks are just beginning to be dissected. Intervention studies in humans aiming to either selectively alter the composition of the intestinal microbiota or to pharmacologically manipulate the microbiota to influence production of their metabolites are crucial next steps. The intestinal microbiome represents a new potential therapeutic target for the treatment of cardio-metabolic diseases.Entities:
Keywords: Atherothrombosis; Gutmicrobiota; Insulin resistance; Obesity; TMAO; Therapy; Vascular inflammation
Mesh:
Year: 2013 PMID: 24216389 PMCID: PMC3977135 DOI: 10.1093/eurheartj/eht467
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983